MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities of marketable
securities
$102,396K
Issuance of common stock
under the atm offering...
$9,810K
Issuance of common stock
upon exercise of...
$1,674K
Disposal (acquisition)
of property and...
-$11K
Net cash provided by
investing activities
$68,888K
Net cash provided by
financing activities
$11,484K
Canceled cashflow
$33,519K
Net increase
(decrease) in cash and cash...
$12,247K
Canceled cashflow
$68,125K
Purchase of marketable
securities
$33,519K
Stock-based compensation
expense
$4,453K
Accounts payable
$3,533K
Deferred revenue
$1,380K
Depreciation and
amortization
$1,269K
Amortization of right-of-use
assets
$786K
Change in fair value of
derivative liability
$12K
Net cash used in
operating activities
-$68,125K
Canceled cashflow
$11,433K
Net loss
-$68,760K
Accrued and other
liabilities
-$4,123K
Prepaid expenses and
other current assets
$3,993K
Net accretion of
discount on marketable...
$1,134K
Operating lease
liabilities
-$878K
Other assets
$670K
Back
Back
Cash Flow
source: myfinsight.com
4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. (FDMT)